XCancer

VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer

Description:

This phase I trial studies the side effects and best dose of vesicular stomatitis virus-human interferon beta-sodium iodide symporter (VSV-hIFNbeta-NIS) with or without ruxolitinib phosphate in treating patients with stage IV endometrial cancer or endometrial cancer that has come back. The study virus, VSV-hIFNbeta-NIS, has been changed so that it has restricted ability to spread to tumor cells and not to healthy cells. It also contains a gene for a protein, NIS, which helps the body concentrate iodine making it possible to track where the virus goes. VSV-hIFNbeta-NIS may be able to kill tumor cells without damaging normal cells. Ruxolitinib phosphate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving VSV-hIFNbeta-NIS with ruxolitinib phosphate may work better in treating patients with endometrial cancer compared to VSV-hIFNbeta-NIS alone.

Sponsor:

Mayo Clinic

Phase:

Phase 1

Contacts:

Jamie N. Bakkum-Gamez, M.D. (PRINCIPAL_INVESTIGATOR)

Government Study Link:

NCT03120624 - Click here to see study on

ClinicalTrials.gov

Sodium Pertechnetate

Isotope(s):
Target(s):
  • NET
Ligand Class: Small Molecules
Inclusion
  • NOTE: histologic confirmation of the original primary tumor is required; patients with the following histologic epithelial cell types are eligible: Endometrioid adenocarcinoma, serous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, carcinosarcoma, adenocarcinoma not otherwise specified (NOS)
  • Group A only: Largest tumor diameter =\< 5 cm
  • NOTE: Group B patients have no maximum tumor size
  • * Measurable stage IVA, stage IVB (with or without measurable disease) or recurrent (with or without measurable disease) endometrial carcinoma
  • NOTE: measurable disease is defined by Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1)
Exclusion
  • Any of the following prior therapies:
  • Known untreated or symptomatic brain metastases
  • * Availability of and patient acceptance of curative therapy
  • Active infection requiring treatment, including any active viral infection, =\< 5 days prior to registration
  • Active or latent tuberculosis or hepatitis